1. Home
  2. CALY vs RARE Comparison

CALY vs RARE Comparison

Compare CALY & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CALY

Callaway Golf Company

N/A

Current Price

$15.83

Market Cap

3.0B

Sector

N/A

ML Signal

N/A

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

HOLD

Current Price

$26.49

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CALY
RARE
Founded
1982
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.5B
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
CALY
RARE
Price
$15.83
$26.49
Analyst Decision
Buy
Strong Buy
Analyst Count
4
20
Target Price
$16.50
$59.10
AVG Volume (30 Days)
1.9M
2.0M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
72.08
7.31
EPS
0.87
N/A
Revenue
$2,060,100,000.00
$673,000,000.00
Revenue This Year
$9.70
$13.12
Revenue Next Year
$3.01
$37.80
P/E Ratio
$18.15
N/A
Revenue Growth
N/A
20.13
52 Week Low
$12.26
$18.29
52 Week High
$20.28
$39.89

Technical Indicators

Market Signals
Indicator
CALY
RARE
Relative Strength Index (RSI) 32.58 46.97
Support Level $14.06 $21.54
Resistance Level $16.33 $27.95
Average True Range (ATR) 0.67 1.41
MACD -0.21 0.08
Stochastic Oscillator 6.34 42.88

Price Performance

Historical Comparison
CALY
RARE

About CALY Callaway Golf Company

Callaway Golf Co is a golf equipment, gear and apparel company with a portfolio of world-wide brands, including Callaway Golf, Odyssey, TravisMathew, and OGIO. Callaway designs, manufactures, and sells high-performance golf clubs, golf balls, apparel, bags, and other accessories-setting the standard for performance in the game of golf. The company has two operating and reportable business segments: Golf Equipment and Apparel, Gear and Other. Geographically, the company operates in United States, Europe, Asia, and Rest of World, of which it derives maximum revenue from United States.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: